RESENDIS ANTONIO LAB


Blending Biology and Computation to understand human diseases.



Who we are

Welcome to the webpage of the Human Systems Biology group in the National Institute for Genomic Medicine at Mexico City, INMEGEN. Our group is interdisciplinary and have the objective to develop a systems biology framework to analyze mainly human diseases and metabolic phenotype in microorganisms through the use of computational models and high-throughput technologies. Currently, our laboratory focuses on the analysis of metabolic alterations in cancer cells by the implementation of genome scale metabolic reconstructions and assess the predictions in terms of experimental data at different scales.

Latest News

Memote: A community driven effort towards a standardized genome-scale metabolic model test suite

by


Several studies have shown that neither the formal representation nor the functional requirements of genome-scale metabolic models (GEMs) are precisely defined. Without a consistent standard, comparability, reproducibility, and interoperability of models across groups and software tools cannot be guaranteed. Here, we present memote (https://github.com/opencobra/memote) an open-source software containing a community-maintained, standardized set of metabolic model tests. The tests cover a range of aspects from annotations to conceptual integrity and can be extended to include experimental datasets for automatic model validation.

Latest Publication

Analysis of Epithelial-Mesenchymal Transition Metabolism Identifies Possible Cancer Biomarkers Useful in Diverse Genetic Backgrounds

Frontiers in Onology 2020

Meztli Matadamas-Guzman, Cecilia Zazueta, Emilio Rojas and Osbaldo Resendis-Antonio

Epithelial-to-mesenchymal transition (EMT) relates to many molecular and cellular alterations that occur when epithelial cells undergo a switch in differentiation generating mesenchymal-like cells with newly acquired migratory and invasive properties. In cancer cells, EMT leads to drug resistance and metastasis. Moreover, differences in genetic backgrounds, even between patients with the same type of cancer, also determine resistance to some treatments. Metabolic rewiring is essential to induce EMT, hence it is important to identify key metabolic elements for this process, which can be later used to treat cancer cells with different genetic backgrounds.